カテゴリー： Global Markets Direct, 医療/バイオ

肝硬変：パイプラインレビュー2019下半期

【英語タイトル】Liver Cirrhosis - Pipeline Review, H2 2019

Global Markets Directが出版した調査資料（GDATA9120324）・商品コード：GDATA9120324
・発行会社（調査会社）：Global Markets Direct
・発行日：2019年11月
・ページ数：106
・レポート言語：英語
・レポート形式：PDF
・納品方法：Eメール（受注後24時間以内）
・調査対象地域：グローバル
・産業分野：製薬及び医療
◆販売価格オプション（消費税別）
Single User（1名様閲覧用）USD2,000 ⇒換算￥216,000見積依頼/購入/質問フォーム
Site License（同一事業所内共有可）USD4,000 ⇒換算￥432,000見積依頼/購入/質問フォーム
Enterprisewide Price（複数事業所内共有可）USD6,000 ⇒換算￥648,000見積依頼/購入/質問フォーム
※販売価格オプションの説明
※お支払金額：換算金額（日本円）＋消費税
※納期：即日〜2営業日（3日以上かかる場合は別途表記又はご連絡）
※お支払方法：納品日＋5日以内に請求書を発行・郵送（請求書発行日より2ヶ月以内に銀行振込、振込先：三菱UFJ銀行/H&Iグローバルリサーチ株式会社、支払期限と方法は調整可能）
【レポートの概要】

Liver Cirrhosis – Pipeline Review, H2 2019
Summary

Global Markets Direct’s latest Pharmaceutical and Healthcare disease pipeline guide Liver Cirrhosis – Pipeline Review, H2 2019, provides an overview of the Liver Cirrhosis (Gastrointestinal) pipeline landscape.

Cirrhosis is scarring of the liver caused by many forms of liver diseases and conditions, such as hepatitis and chronic alcohol abuse. The scar tissue damages the normal structure of the liver which affects the normal flow of blood through the liver. Symptoms include loss of appetite, itchy skin, weight loss, tiredness and weakness and nausea. Treatment includes liver transplant surgery.

Report Highlights

Global Markets Direct’s Pharmaceutical and Healthcare latest pipeline guide Liver Cirrhosis – Pipeline Review, H2 2019, provides comprehensive information on the therapeutics under development for Liver Cirrhosis (Gastrointestinal), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.

The Liver Cirrhosis (Gastrointestinal) pipeline guide also reviews of key players involved in therapeutic development for Liver Cirrhosis and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Phase III, Phase II, Phase I, Preclinical and Discovery stages are 1, 8, 3, 12 and 5 respectively. Similarly, the Universities portfolio in Preclinical stages comprises 1 molecule, respectively.

Liver Cirrhosis (Gastrointestinal) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from Global Markets Direct’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

Scope

- The pipeline guide provides a snapshot of the global therapeutic landscape of Liver Cirrhosis (Gastrointestinal).
- The pipeline guide reviews pipeline therapeutics for Liver Cirrhosis (Gastrointestinal) by companies and universities/research institutes based on information derived from company and industry-specific sources.
- The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.
- The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
- The pipeline guide reviews key companies involved in Liver Cirrhosis (Gastrointestinal) therapeutics and enlists all their major and minor projects.
- The pipeline guide evaluates Liver Cirrhosis (Gastrointestinal) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.
- The pipeline guide encapsulates all the dormant and discontinued pipeline projects.
- The pipeline guide reviews latest news related to pipeline therapeutics for Liver Cirrhosis (Gastrointestinal)

Reasons to buy

- Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.
- Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.
- Find and recognize significant and varied types of therapeutics under development for Liver Cirrhosis (Gastrointestinal).
- Classify potential new clients or partners in the target demographic.
- Develop tactical initiatives by understanding the focus areas of leading companies.
- Plan mergers and acquisitions meritoriously by identifying key players and it’s most promising pipeline therapeutics.
- Formulate corrective measures for pipeline projects by understanding Liver Cirrhosis (Gastrointestinal) pipeline depth and focus of Indication therapeutics.
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
- Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.

【レポートの目次】

Table of Contents
List of Tables
List of Figures
Introduction
Global Markets Direct Report Coverage
Liver Cirrhosis – Overview
Liver Cirrhosis – Therapeutics Development
Pipeline Overview
Pipeline by Companies
Pipeline by Universities/Institutes
Products under Development by Companies
Products under Development by Universities/Institutes
Liver Cirrhosis – Therapeutics Assessment
Assessment by Target
Assessment by Mechanism of Action
Assessment by Route of Administration
Assessment by Molecule Type
Liver Cirrhosis – Companies Involved in Therapeutics Development
Advantagene Inc
AlfaSigma SpA
Bristol-Myers Squibb Co
Galectin Therapeutics Inc
Gilead Sciences Inc
Grifols SA
International Stem Cell Corp
Mina Therapeutics Ltd
Novo Nordisk AS
Pharmicell Co Ltd
Promethera Biosciences SA
Rohto Pharmaceutical Co Ltd
Versantis AG
VESSL Therapeutics Ltd
Liver Cirrhosis – Drug Profiles
7-E – Drug Profile
Product Description
Mechanism Of Action
R&D Progress
ADR-001 – Drug Profile
Product Description
Mechanism Of Action
R&D Progress
albumin (human) – Drug Profile
Product Description
Mechanism Of Action
R&D Progress
BCD-800 – Drug Profile
Product Description
Mechanism Of Action
R&D Progress
belapectin – Drug Profile
Product Description
Mechanism Of Action
R&D Progress
BMS-986263 – Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Cellgram-LC – Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Gene Therapy for Liver Cirrhosis – Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Gene Therapy to Activate MMP8 for Liver Cirrhosis – Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Gene Therapy to Activate ZSCAN4 for Liver Cirrhosis – Drug Profile
Product Description
Mechanism Of Action
R&D Progress
GXHPC-1 – Drug Profile
Product Description
Mechanism Of Action
R&D Progress
HepaStem – Drug Profile
Product Description
Mechanism Of Action
R&D Progress
LAE-101 – Drug Profile
Product Description
Mechanism Of Action
R&D Progress
LAE-102 – Drug Profile
Product Description
Mechanism Of Action
R&D Progress
LAE-103 – Drug Profile
Product Description
Mechanism Of Action
R&D Progress
LAE-104 – Drug Profile
Product Description
Mechanism Of Action
R&D Progress
MTL-CEBPA – Drug Profile
Product Description
Mechanism Of Action
R&D Progress
ND-654 – Drug Profile
Product Description
Mechanism Of Action
R&D Progress
NN-9931 – Drug Profile
Product Description
Mechanism Of Action
R&D Progress
OC-101 – Drug Profile
Product Description
Mechanism Of Action
R&D Progress
pegbelfermin – Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Peptide to Inhibit C/EBP-Beta for Gastrointestinal and Respiratory Diseases – Drug Profile
Product Description
Mechanism Of Action
R&D Progress
PRI-724 – Drug Profile
Product Description
Mechanism Of Action
R&D Progress
rifaximin SSD – Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Stem Cell Therapy for Alpha-Antitrypsin Deficiency, Crigler-Najjar Syndrome and Liver Cirrhosis – Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Stem Cell Therapy for Liver Cirrhosis – Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Stem Cell Therapy for Liver Cirrhosis – Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Stem Cell Therapy for Liver Fibrosis and Liver Cirrhosis – Drug Profile
Product Description
Mechanism Of Action
R&D Progress
TLY-012 – Drug Profile
Product Description
Mechanism Of Action
R&D Progress
VS-01 – Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Liver Cirrhosis – Dormant Projects
Liver Cirrhosis – Discontinued Products
Liver Cirrhosis – Product Development Milestones
Featured News & Press Releases
Sep 17, 2019: Galectin Therapeutics and Providence Cancer Institute receive patent on the use of Belapectin (GR-MD-02) in Cancer Immunotherapy
Appendix
Methodology
Coverage
Secondary Research
Primary Research
Expert Panel Validation
Contact Us
Disclaimer

List of Tables
Number of Products under Development for Liver Cirrhosis, H2 2019
Number of Products under Development by Companies, H2 2019
Number of Products under Development by Companies, H2 2019 (Contd..1), H2 2019
Number of Products under Development by Universities/Institutes, H2 2019
Products under Development by Companies, H2 2019
Products under Development by Companies, H2 2019 (Contd..1), H2 2019
Products under Development by Universities/Institutes, H2 2019
Number of Products by Stage and Target, H2 2019
Number of Products by Stage and Mechanism of Action, H2 2019
Number of Products by Stage and Route of Administration, H2 2019
Number of Products by Stage and Molecule Type, H2 2019
Liver Cirrhosis - Pipeline by Advantagene Inc, H2 2019
Liver Cirrhosis - Pipeline by AlfaSigma SpA, H2 2019
Liver Cirrhosis - Pipeline by Bristol-Myers Squibb Co, H2 2019
Liver Cirrhosis - Pipeline by Galectin Therapeutics Inc, H2 2019
Liver Cirrhosis - Pipeline by Gilead Sciences Inc, H2 2019
Liver Cirrhosis - Pipeline by Grifols SA, H2 2019
Liver Cirrhosis - Pipeline by International Stem Cell Corp, H2 2019
Liver Cirrhosis - Pipeline by Mina Therapeutics Ltd, H2 2019
Liver Cirrhosis - Pipeline by Novo Nordisk AS, H2 2019
Liver Cirrhosis - Pipeline by Pharmicell Co Ltd, H2 2019
Liver Cirrhosis - Pipeline by Promethera Biosciences SA, H2 2019
Liver Cirrhosis - Pipeline by Rohto Pharmaceutical Co Ltd, H2 2019
Liver Cirrhosis - Pipeline by Versantis AG, H2 2019
Liver Cirrhosis - Pipeline by VESSL Therapeutics Ltd, H2 2019
Liver Cirrhosis - Dormant Projects, H2 2019
Liver Cirrhosis - Discontinued Products, H2 2019

List of Figures
Number of Products under Development for Liver Cirrhosis, H2 2019 9
Number of Products under Development by Companies, H2 2019 10
Number of Products by Targets, H2 2019 17
Number of Products by Stage and Targets, H2 2019 17
Number of Products by Mechanism of Actions, H2 2019 19
Number of Products by Stage and Mechanism of Actions, H2 2019 19
Number of Products by Routes of Administration, H2 2019 21
Number of Products by Stage and Routes of Administration, H2 2019 21
Number of Products by Top 10 Molecule Types, H2 2019 23
Number of Products by Stage and Top 10 Molecule Types, H2 2019 23

【掲載企業】

Advantagene Inc
AlfaSigma SpA
Bristol-Myers Squibb Co
Galectin Therapeutics Inc
Gilead Sciences Inc
Grifols SA
International Stem Cell Corp
Mina Therapeutics Ltd
Novo Nordisk AS
Pharmicell Co Ltd
Promethera Biosciences SA
Rohto Pharmaceutical Co Ltd
Versantis AG
VESSL Therapeutics Ltd

★調査レポート[肝硬変：パイプラインレビュー2019下半期] (コード：GDATA9120324)販売に関する免責事項を必ずご確認ください。
★調査レポート[肝硬変：パイプラインレビュー2019下半期]についてメールでお問い合わせ
◆関連市場調査レポート◆
  • 急性呼吸窮迫症候群：パイプラインレビュー2019下半期
    GDATA9120306 / Global Markets Direct / 2019年11月 / ...Acute Respiratory Distress Syndrome - Pipeline Review, H2 2019 Summary Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Acute Respiratory Distress Syndrome - Pipeline Review, H2 2019, provides an overview of the Acute Respiratory Distress Syndrome (Respiratory) pipeline landscape. Acute respiratory distress syndrome (ARDS) occurs when fluid fills up the air sacs in lungs. This leads to low oxygen levels in the blood. Common causes of ARDS include sepsis, inhalation of harmful substances, severe pneumonia and head or chest injury. Signs and symptoms of ARDS include severe shortness of breath, labored and unusually rapid breathing, low blood pressure...
  • 褥瘡 ：パイプラインレビュー2019下半期
    GDATA9120197 / Global Markets Direct / 2019年9月 / ...Pressure Ulcers - Pipeline Review, H2 2019 Summary Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Pressure Ulcers - Pipeline Review, H2 2019, provides an overview of the Pressure Ulcers (Dermatology) pipeline landscape. Pressure ulcers are an injury that breaks down the skin and underlying tissue. The parts of the body most at risk of developing pressure ulcers are those that are not covered by a large amount of body fat and are in direct contact with a supporting surface (bed or a wheelchair). Causes include continuous pressure, friction and shear. Treatment includes antibiotics and nutrition. Report Highlights...
  • アミロイドーシス：パイプラインレビュー2019下半期
    GDATA9120309 / Global Markets Direct / 2019年11月 / ...Amyloidosis - Pipeline Review, H2 2019 Summary Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Amyloidosis - Pipeline Review, H2 2019, provides an overview of the Amyloidosis (Metabolic Disorders) pipeline landscape. Abnormal accumulation of amyloid protein in the tissues results in a group of diseases known as amyloidosis. It may affect the shape and functioning of the organ eventually leading to organ failure. Predisposing factors are misfolding of abnormal protein called the light chain and its subsequent deposition in the body. It may also occur as a result of dialysis. Symptoms include fatigue, chest pain, swelling and breathing...
  • 脳脊髄炎：パイプラインレビュー2019下半期
    GDATA9120316 / Global Markets Direct / 2019年11月 / ...Encephalomyelitis - Pipeline Review, H2 2019 Summary Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Encephalomyelitis - Pipeline Review, H2 2019, provides an overview of the Encephalomyelitis (Central Nervous System) pipeline landscape. Encephalomyelitis is an inflammation of the brain and spinal cord. Encephalomyelitis can be caused by a variety of conditions that lead to irritation of the brain and spinal cord. Among the common causes of encephalomyelitis are viruses which infect the nervous tissues. Signs and symptoms include neck stiffness, headache, and fever. Treatment includes antibiotics and corticosteroids. Report Highlights Global Markets Direct's Pharmaceutical and Healthcare latest pipeline...
  • 勃起不全：パイプラインレビュー2019下半期
    GDATA9120317 / Global Markets Direct / 2019年11月 / ...Erectile Dysfunction - Pipeline Review, H2 2019 Summary Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Erectile Dysfunction - Pipeline Review, H2 2019, provides an overview of the Erectile Dysfunction (Male Health) pipeline landscape. Erectile dysfunction, or ED, is the inability of a man to have an erection hard enough to have sexual intercourse. It can also be known as impotence. The predisposing factors include tobacco usage, overweight, injuries, drug and alcohol use and medications, including antidepressants, antihistamines and medications to treat high blood pressure, pain or prostate cancer. Report Highlights Global Markets Direct's Pharmaceutical and Healthcare latest...
  • 5 ‘ヌクレオチダーゼ：パイプラインレビュー2019下半期
    GDATA9120081 / Global Markets Direct / 2019年8月 / ...5' Nucleotidase - Pipeline Review, H2 2019 Summary 5' Nucleotidase (Ecto 5' Nucleotidase or CD73 or NT5E or EC 3.1.3.5) - 5′-Nucleotidase (5NT) is an intrinsic membrane glycoprotein that is present as an enzyme in a wide variety of mammalian cells. It catalyzes the phosphorylytic cleavage of 5'nucleotides. 5' Nucleotidase (Ecto 5' Nucleotidase or CD73 or NT5E or EC 3.1.3.5) pipeline Target constitutes close to 30 molecules. Out of which approximately 27 molecules are developed by companies and remaining by the universities/institutes. The molecules developed by companies in Phase II, Phase I, Preclinical and Discovery stages are 3, 4, 11...
  • 原発性硬化性胆管炎：パイプラインレビュー2019下半期
    GDATA9120198 / Global Markets Direct / 2019年9月 / ...Primary Sclerosing Cholangitis - Pipeline Review, H2 2019 Summary Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Primary Sclerosing Cholangitis - Pipeline Review, H2 2019, provides an overview of the Primary Sclerosing Cholangitis (Gastrointestinal) pipeline landscape. Primary sclerosing cholangitis (PSC) is a chronic liver disease characterized by a progressive course of cholestasis with inflammation and fibrosis of the intrahepatic and extra hepatic bile ducts. Symptoms include abdominal pain, chills, diarrhea, fatigue, itchiness and weight loss. The predisposing factors include age and inflammatory bowel diseases. Treatment includes antibiotics and bile-acid-binding drugs. Report Highlights Global Markets Direct's Pharmaceutical and Healthcare...
  • 痳病：パイプラインレビュー2019下半期
    GDATA9120320 / Global Markets Direct / 2019年11月 / ...Gonorrhea - Pipeline Review, H2 2019 Summary Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Gonorrhea - Pipeline Review, H2 2019, provides an overview of the Gonorrhea (Infectious Disease) pipeline landscape. Gonorrhea is a sexually transmitted disease (STD) caused by Neisseria gonorrhoeae bacterium. It can infect both males and females. The bacteria target the cells of the mucous membranes including surfaces of the urethra, vagina, cervix and endometrium, lining of the eyelid, the throat and fallopian tubes. Symptoms include painful urination, pus-like discharge from penis, increased vaginal discharge, abdominal pain and pelvic pain. Treatment includes antibiotics. Report Highlights...
  • Toll様受容体4：パイプラインレビュー2019下半期
    GDATA9120143 / Global Markets Direct / 2019年8月 / ...Toll Like Receptor 4 - Pipeline Review, H2 2019 Summary Toll Like Receptor 4 (hToll or CD284 or TLR4) - Toll-like receptor 4 is a protein encoded by the TLR4 gene. This receptor is mostly expressed in placenta, and in myelomonocytic subpopulation of the leukocytes. It is involved in LPS-independent inflammatory responses triggered by free fatty acids, such as palmitate, and Ni2+. It responses are triggered by Ni2+ require non-conserved. In complex with TLR6 promotes sterile inflammation in monocytes in response to oxidized low-density lipoprotein (oxLDL). Toll Like Receptor 4 (hToll or CD284 or TLR4) pipeline Target constitutes close to...
  • 化膿性汗腺炎：パイプラインレビュー2019下半期
    GDATA9120187 / Global Markets Direct / 2019年9月 / ...Hidradenitis Suppurativa - Pipeline Review, H2 2019 Summary Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Hidradenitis Suppurativa - Pipeline Review, H2 2019, provides an overview of the Hidradenitis Suppurativa (Dermatology) pipeline landscape. Hidradenitis suppurativa is a chronic skin condition that features pea-sized to marble-sized lumps under the skin. Also known as acne inversa, these deep-seated lumps typically develop where skin rubs together such as the armpits, groin, between the buttocks and under the breasts. Report Highlights Global Markets Direct's Pharmaceutical and Healthcare latest pipeline guide Hidradenitis Suppurativa - Pipeline Review, H2 2019, provides comprehensive information on the...

    • ◆H&Iグローバルリサーチのお客様（例）◆